Cite
MLA Citation
Howard L. Kaufman et al.. “Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials.” Journal for immunotherapy of cancer, vol. 5, no. 1, 2017, p. . http://access.bl.uk/ark:/81055/vdc_100137784968.0x000007